- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Boehringer Ingelheim launches EURICAN L4 vaccine for leptospirosis in dogs
Ingelheim: Boehringer Ingelheim has begun its launch of EURICAN L4, delivering a new vaccine to protect dogs against the growing threat of leptospirosis, a severe and reemerging infectious disease. EURICAN L4 is now available to veterinary practices in France, with additional countries in Europe to follow in 2025.
Leptospirosis is caused by Leptospira bacteria, of which there are more than 300 serovars within 25 serogroups.
The new, non-adjuvanted EURICAN L4 vaccine provides effective immunity against four key Leptospira serogroups, including L. Australis, which has emerged due to changes in the epidemiology of canine leptospirosis3, as well as L. Canicola, L. Icterohaemorrhagiae and L. Grippotyphosa. A 2017-2020 study identified L. Icterohaemorrhagiae (53%) and L. Australis (13%) as the most prevalent Leptospira serogroups circulating in dogs in Europe.
Already two weeks after primary vaccination, dogs can benefit from EURICAN L4’s outstanding efficacy profile: prevention of mortality and clinical signs, and prevention or reduction of infection, urinary excretion, renal carriage, and renal lesions. The first vaccination can be given to puppies starting at seven weeks of age, followed by a booster four weeks later, and then a yearly vaccination.
“As part of our ongoing careful monitoring of challenges to the health of animals, we recognized an opportunity to develop an innovative vaccine to address the current epidemiological situation of leptospirosis,” said Erich Schött, Head of Pet Vaccines at Boehringer Ingelheim. “We are pleased to introduce EURICAN L4 – with outstanding efficacy against relevant Leptospira serogroups in Europe – to help protect more dogs from the increasing dangers of this serious disease.”
Leptospirosis is a severe infectious disease caused by Leptospira bacteria that are widespread globally. This multi-organ disease, which particularly affects the kidney and liver, can be fatal for dogs. Soil and water, contaminated by rodent urine carrying the bacteria, are the main sources of dogs’ infection. Leptospirosis is more common in warm climates with high annual rainfall, but it can occur anywhere, especially after heavy rainfall and flooding. The risk of infection is increasing in Europe due to climate change and urbanization.
“Vaccination against leptospirosis is crucial for dogs around the world, with veterinarians providing important guidance to pet owners,” Schött added. “We are proud to be a leader in protecting pets from infectious diseases – and helping to keep animals healthy.”
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751